| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, P Tomczak, MD Michaelson, RM Bukowski, O Rixe, ... New England Journal of Medicine 356 (2), 115-124, 2007 | 7280 | 2007 |
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ... The Lancet 368 (9544), 1329-1338, 2006 | 3255 | 2006 |
| Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal … RJ Motzer, MD Michaelson, BG Redman, GR Hudes, G Wilding, RA Figlin, ... Journal of Clinical Oncology 24 (1), 16-24, 2006 | 2160 | 2006 |
| Sunitinib in patients with metastatic renal cell carcinoma RJ Motzer, BI Rini, RM Bukowski, BD Curti, DJ George, GR Hudes, ... Jama 295 (21), 2516-2524, 2006 | 1634 | 2006 |
| Isolation of a candidate human hematopoietic stem-cell population. CM Baum, IL Weissman, AS Tsukamoto, AM Buckle, B Peault Proceedings of the National Academy of Sciences 89 (7), 2804-2808, 1992 | 1552 | 1992 |
| Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor MC Heinrich, RG Maki, CL Corless, CR Antonescu, A Harlow, D Griffith, ... Journal of clinical oncology 26 (33), 5352-5359, 2008 | 988 | 2008 |
| Activity of sunitinib in patients with advanced neuroendocrine tumors MH Kulke, HJ Lenz, NJ Meropol, J Posey, DP Ryan, J Picus, E Bergsland, ... Journal of Clinical Oncology 26 (20), 3403-3410, 2008 | 765 | 2008 |
| Human hematopoietic stem cell A Tsukamoto, CM Baum, Y Aihara, I Weissman US Patent 5,061,620, 1991 | 667* | 1991 |
| Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane HJ Burstein, AD Elias, HS Rugo, MA Cobleigh, AC Wolff, PD Eisenberg, ... Journal of Clinical Oncology 26 (11), 1810-1816, 2008 | 647 | 2008 |
| Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins SE DePrimo, CL Bello, J Smeraglia, CM Baum, D Spinella, BI Rini, ... Journal of translational medicine 5, 1-11, 2007 | 386 | 2007 |
| Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma RJ Motzer, RM Bukowski, RA Figlin, TE Hutson, MD Michaelson, ST Kim, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 273 | 2008 |
| Implantation and maintenance of functional human bone marrow in SCID-hu mice S Kyoizumi, CM Baum, H Kaneshima, JM McCune, EJ Yee, R Namikawa | 261 | 1992 |
| Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor A Norden-Zfoni, J Desai, J Manola, P Beaudry, J Force, R Maki, ... Clinical Cancer Research 13 (9), 2643-2650, 2007 | 250 | 2007 |
| Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) RJ Motzer, TE Hutson, P Tomczak, MD Michaelson, RM Bukowski, O Rixe, ... Journal of Clinical Oncology 24 (18_suppl), LBA3-LBA3, 2006 | 204 | 2006 |
| Lymphoid reconstitution of the human fetal thymus in SCID mice with CD34+ precursor cells. B Peault, IL Weissman, C Baum, JM McCune, A Tsukamoto The Journal of experimental medicine 174 (5), 1283-1286, 1991 | 182 | 1991 |
| Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure GD Demetri, MC Heinrich, JA Fletcher, CDM Fletcher, ... Clinical Cancer Research 15 (18), 5902-5909, 2009 | 178 | 2009 |
| Human hematopoietic stem cell A Tsukamoto, CM Baum, Y Aihara, I Weissman US Patent 5,716,827, 1998 | 170 | 1998 |
| Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST GD Demetri, AT Van Oosterom, M Blackstein, C Garrett, M Shah, ... Journal of Clinical Oncology 23 (16_suppl), 4000-4000, 2005 | 167 | 2005 |
| SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic … GD Demetri, J Desai, JA Fletcher, JA Morgan, CDM Fletcher, ... Journal of Clinical Oncology 22 (14_suppl), 3001-3001, 2004 | 166 | 2004 |
| Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) RJ Motzer, BI Rini, MD Michaelson, BG Redman, GR Hudes, G Wilding, ... Journal of Clinical Oncology 23 (16_suppl), 4508-4508, 2005 | 163 | 2005 |
